|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ridge CA, Pua BB and Madoff DC:
Epidemiology and staging of renal cell carcinoma. Semin Intervent
Radiol. 31:3–8. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jansi Prema KS, Devanathan KS and Kurien
AA: Renal cell carcinoma with t(6,11): A case report and review of
literature. Indian J Pathol Microbiol. 60:574–576. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gill DM, Hahn AW, Hale P and Maughan BL:
Overview of current and future first-line systemic therapy for
metastatic clear cell renal cell carcinoma. Curr Treat Options
Oncol. 19:62018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Margulis V, Master VA, Cost NG, Leibovich
BC, Joniau S, Kuczyk M, Mulders PF, Kirkali Z, Wirth MP, Hirao Y,
et al: International consultation on urologic diseases and the
European Association of Urology international consultation on
locally advanced renal cell carcinoma. Eur Urol. 60:673–683. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cirilo PDR, de Sousa Andrade LN, Corrêa
BRS, Qiao M, Furuya TK, Chammas R and Penalva LOF: MicroRNA-195
acts as an anti-proliferative miRNA in human melanoma cells by
targeting Prohibitin 1. BMC Cancer. 17:7502017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gang L, Qun L, Liu WD, Li YS, Xu YZ and
Yuan DT: MicroRNA-34a promotes cell cycle arrest and apoptosis and
suppresses cell adhesion by targeting DUSP1 in osteosarcoma. Am J
Transl Res. 9:5388–5399. 2017.PubMed/NCBI
|
|
11
|
Xu Y, Du J, Zhang P, Zhao X, Li Q, Jiang
A, Jiang D, Tang G, Jiang Y, Wang J, et al: MicroRNA-125a-5p
mediates 3T3-L1 preadipocyte proliferation and differentiation.
Molecules. 23:E3172018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song H, Rao Y, Zhang G and Kong X:
MicroRNA-384 inhibits the growth and invasion of renal cell
carcinoma cells by targeting astrocyte elevated gene 1. Oncol Res.
Aug 25–2017.(Epub ahead of print).
|
|
13
|
Wang X, Li H, Cui L, Feng J and Fan Q:
MicroRNA-182 suppresses clear cell renal cell carcinoma migration
and invasion by targeting IGF1R. Neoplasma. 63:717–725. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu B, Wang J and Jin X: MicroRNA-138
suppresses cell proliferation and invasion of renal cell carcinoma
by directly targeting SOX9. Oncol Lett. 14:7583–7588.
2017.PubMed/NCBI
|
|
15
|
Chilosi M, Caliò A, Rossi A, Gilioli E,
Pedica F, Montagna L, Pedron S, Confalonieri M, Doglioni C, Ziesche
R, et al: Epithelial to mesenchymal transition-related proteins
ZEB1, β-catenin, and β-tubulin-III in idiopathic pulmonary
fibrosis. Mod Pathol. 30:26–38. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cruz-Solbes AS and Youker K: Epithelial to
mesenchymal transition (EMT) and endothelial to mesenchymal
transition (EndMT): Role and implications in kidney fibrosis.
Results Probl Cell Differ. 60:345–372. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fedele M, Cerchia L and Chiappetta G: The
epithelial-to-mesenchymal transition in breast cancer: Focus on
basal-like carcinomas. Cancers (Basel). 9:E1342017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Saito N, Mine N, Kufe DW, Von Hoff DD and
Kawabe T: CBP501 inhibits EGF-dependent cell migration, invasion
and epithelial-to-mesenchymal transition of non-small cell lung
cancer cells by blocking KRas to calmodulin binding. Oncotarget.
8:74006–74018. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zou JX, Revenko AS, Li LB, Gemo AT and
Chen HW: ANCCA, an estrogen-regulated AAA+ ATPase
coactivator for ERalpha, is required for coregulator occupancy and
chromatin modification. Proc Natl Acad Sci USA. 104:18067–18072.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Beroukhim R, Mermel CH, Porter D, Wei G,
Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J,
Urashima M, et al: The landscape of somatic copy-number alteration
across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Raeder MB, Birkeland E, Trovik J, Krakstad
C, Shehata S, Schumacher S, Zack TI, Krohn A, Werner HM, Moody SE,
et al: Integrated genomic analysis of the 8q24 amplification in
endometrial cancers identifies ATAD2 as essential to MYC-dependent
cancers. PLoS One. 8:e548732013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng L, Li T, Zhang Y, Guo Y, Yao J, Dou
L and Guo K: Oncogene ATAD2 promotes cell proliferation, invasion
and migration in cervical cancer. Oncol Rep. 33:2337–2344. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cattaneo M, Morozumi Y, Perazza D,
Boussouar F, Jamshidikia M, Rousseaux S, Verdel A and Khochbin S:
Lessons from yeast on emerging roles of the ATAD2 protein family in
gene regulation and genome organization. Mol Cells. 37:851–856.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hou M, Huang R, Song Y, Feng D, Jiang Y
and Liu M: ATAD2 overexpression is associated with progression and
prognosis in colorectal cancer. Jpn J Clin Oncol. 46:222–227. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang M, Zhang C, Du W, Yang X and Chen Z:
ATAD2 is overexpressed in gastric cancer and serves as an
independent poor prognostic biomarker. Clin Transl Oncol.
18:776–781. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hakimi AA, Furberg H, Zabor EC, Jacobsen
A, Schultz N, Ciriello G, Mikklineni N, Fiegoli B, Kim PH, Voss MH,
et al: An epidemiologic and genomic investigation into the obesity
paradox in renal cell carcinoma. J Natl Cancer Inst. 105:1862–1870.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Massari F, Di Nunno V, Ciccarese C, Graham
J, Porta C, Comito F, Cubelli M, Iacovelli R and Heng DYC: Adjuvant
therapy in renal cell carcinoma. Cancer Treat Rev. 60:152–157.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu J, Ma X, Zhang Y, Ni D, Ai Q, Li H and
Zhang X: Establishment of a miRNA-mRNA regulatory network in
metastatic renal cell carcinoma and screening of potential
therapeutic targets. Tumour Biol. 37:15649–15663. 2016. View Article : Google Scholar
|
|
30
|
Xu SY, Xu PF and Gao TT: MiR-372-3p
inhibits the growth and metastasis of osteosarcoma cells by
targeting FXYD6. Eur Rev Med Pharmacol Sci. 22:62–69.
2018.PubMed/NCBI
|
|
31
|
Yu J, Jin L, Jiang L, Gao L, Zhou J, Hu Y,
Li W, Zhi Q and Zhu X: Serum miR-372 is a diagnostic and prognostic
biomarker in patients with early colorectal cancer. Anticancer
Agents Med Chem. 16:424–431. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu G, Wang Y, Lu X, He H, Liu H, Meng X,
Xia S, Zheng K and Liu B: Low miR-372 expression correlates with
poor prognosis and tumor metastasis in hepatocellular carcinoma.
BMC Cancer. 15:1822015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kong X, Qian X, Duan L, Liu H, Zhu Y and
Qi J: MicroRNA-372 suppresses migration and invasion by targeting
p65 in human prostate cancer cells. DNA Cell Biol. 35:828–835.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu BL, Sun KX, Zong ZH, Chen S and Zhao
Y: MicroRNA-372 inhibits endometrial carcinoma development by
targeting the expression of the Ras homolog gene family member C
(RhoC). Oncotarget. 7:6649–6664. 2016.PubMed/NCBI
|
|
35
|
Ragusa M, Statello L, Maugeri M, Majorana
A, Barbagallo D, Salito L, Sammito M, Santonocito M, Angelica R,
Cavallaro A, et al: Specific alterations of the microRNA
transcriptome and global network structure in colorectal cancer
after treatment with MAPK/ERK inhibitors. J Mol Med (Berl).
90:1421–1438. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen H, Zhang Z, Lu Y, Song K, Liu X, Xia
F and Sun W: Downregulation of ULK1 by microRNA-372 inhibits the
survival of human pancreatic adenocarcinoma cells. Cancer Sci.
108:1811–1819. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tian RQ, Wang XH, Hou LJ, Jia WH, Yang Q,
Li YX, Liu M, Li X and Tang H: MicroRNA-372 is down-regulated and
targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human
cervical cancer, which may contribute to tumorigenesis. J Biol
Chem. 286:25556–25563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ciró M, Prosperini E, Quarto M, Grazini U,
Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M,
Christensen J, et al: ATAD2 is a novel cofactor for MYC,
overexpressed and amplified in aggressive tumors. Cancer Res.
69:8491–8498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hwang HW, Ha SY, Bang H and Park CK: ATAD2
as a poor prognostic marker for hepatocellular carcinoma after
curative resection. Cancer Res Treat. 47:853–861. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wan WN, Zhang YX, Wang XM, Liu YJ, Zhang
YQ, Que YH and Zhao WJ: ATAD2 is highly expressed in ovarian
carcinomas and indicates poor prognosis. Asian Pac J Cancer Prev.
15:2777–2783. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shang P, Meng F, Liu Y and Chen X:
Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its
correlation with tumor progression and poor prognosis. Tumour Biol.
36:4479–4485. 2015. View Article : Google Scholar : PubMed/NCBI
|
